Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD146 CAR-T cells + GPC3 CAR-T cells
- Development stage
- Unknown
- Lead developer
- Essen Biotech
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD146 CAR-T cells + GPC3 CAR-T cells is a sequential chimeric antigen receptor (CAR) T-cell therapy being developed by Essen Biotech for the treatment of advanced relapsed or refractory ovarian cancer, including ovarian clear cell carcinoma (OCCC). The therapeutic regimen involves lymphodepleting chemotherapy with cyclophosphamide and fludarabine, followed by the sequential intravenous infusion of autologous CAR-T cells targeting CD146 (Arm A) and subsequently CAR-T cells targeting Glypican-3 (GPC3) (Arm B). CD146 (Melanoma Cell Adhesion Molecule) and GPC3 are both highly expressed in various solid tumors, and this dual-targeting sequential approach is designed to address tumor heterogeneity and enhance the anti-tumor response in patients with advanced ovarian malignancies.
- Other names
- CD146 CAR-T cells-Essen Biotech-ovarian cancerCD-146 CAR-T cells-Essen Biotech-ovarian cancerCD 146 CAR-T cells-Essen Biotech-ovarian cancerGPC3/CD146 CAR-T cellsGPC3-targeted CAR-T cellsGPC-3-targeted CAR-T cellsGPC 3-targeted CAR-T cellsCD146-targeted CAR-T cellsCD-146-targeted CAR-T cellsCD 146-targeted CAR-T cells
02
Targets
MCAMGPC3 (Glypican-3)
Beyond the preview
Go deeper on CD146 CAR-T cells + GPC3 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD146 CAR-T cells + GPC3 CAR-T cells.